Share Price, page-3794

Beginning to wonder if FDA approval will be met with a muted response from the market. For longs this isn’t an issue, greater things are to come. FDA approval is the golden ticket to establish Neuren as a bona fide earning company and further give confidence to investors that the drugs under Neuren’s care will impact positively on the disorders they seek to treat in particular NNZ-2591.

For others looking to capitalise on a spike or some other short term outlook, it may be unfortunate that Neuren receives approval in a year that looks set to be a stressful one for the economy at large. I would suggest Neuren may experience a subdued rise over the coming months post approval. The real kicker for me would be successful results for NNZ-2591, having this in hand would provide a solid bulwark of positive market anticipation in a year of potential turbulence. Until then I believe Neuren will be at the whim of market turmoil, but I’m confident that the stock will by the end of the year or into early 2024 show an adequate valuation and remain steady while others flail around it.